Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

Factor XI (FXI)-deficient patients may develop excessive bleeding after trauma or surgery. Replacement therapy should be considered in high-risk situations, especially when FXI levels are below 20 IU dL(−1). HEMOLEVEN is a human plasma-derived factor XI concentrate available in France since 1992, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauduer, F, de Raucourt, E, Boyer-Neumann, C, Trossaert, M, Beurrier, P, Faradji, A, Peynet, J, Borg, J-Y, Chamouni, P, Chatelanaz, C, Henriet, C, Bridey, F, Goudemand, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657494/
https://www.ncbi.nlm.nih.gov/pubmed/25817556
http://dx.doi.org/10.1111/hae.12655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657494/
https://www.ncbi.nlm.nih.gov/pubmed/25817556
http://dx.doi.org/10.1111/hae.12655

Ejemplares similares